Skip to main content

Table 1 Comparison of baseline clinicopathological characteristics based on PD-1 and PD-L1 expression of CRC patients in TCGA and FUSCC cohorts

From: Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer

 

TCGA Cohort (N = 356)

FUSCC Cohort (N = 276)

 

Cases

PD-1

P a

PD-L1

P a

Cases

PD-1

P a

PD-L1

P a

No. (%)

Low

High

 

Low

High

 

No. (%)

Low

High

 

Low

High

 

Age (years)

  ≤ 60

137 (38.5)

68 (41.2)

69 (36.1)

0.325

21 (38.2)

116 (38.5)

0.960

170 (61.6)

100 (58.8)

70 (66.0)

0.231

85 (61.6)

85 (61.6)

1.000

  > 60

219 (35.7)

97 (58.8)

122 (63.9)

 

34 (61.8)

185 (61.5)

 

106 (8.4)

70 (41.7)

36 (34.0)

 

53 (38.4)

53 (38.4)

Gender

 Male

199 (55.9)

91 (55.2)

108 (56.5)

0.792

33 (60.0)

166 (55.1)

0.505

166 (60.1)

102 (60.0)

64 (60.4)

0.950

88 (63.8)

78 (56.5)

0.219

 Female

157 (44.1)

74 (44.8)

83 (43.5)

 

22 (40.0)

135 (44.9)

 

110 (39.9)

68 (40.0)

42 (39.6)

 

50 (36.2)

60 (43.5)

Primary site

 Colon

269 (75.6)

115 (69.7)

154 (80.6)

0.017

46 (83.6)

223 (74.1)

0.130

129 (46.7)

84 (49.4)

45 (42.5)

0.260

65 (47.1)

64 (46.4)

0.904

 Rectum

87 (24.4)

50 (30.3)

37 (19.4)

 

9 (16.4)

78 (25.9)

 

147 (53.3)

86 (50.6)

61 (57.5)

 

73 (52.9)

74 (53.6)

Histological type

 Adenocarcinoma

316 (88.8)

149 (90.3)

167 (87.4)

0.393

50 (90.9)

266 (88.4)

0.584

261 (94.6)

158 (92.9)

103 (97.2)

0.132

132 (95.6)

129 (93.5)

0.426

 Mucinous/SRCC

40 (11.2)

16 (9.7)

24 (12.6)

 

5 (9.1)

35 (11.6)

 

15 (5.4)

12 (7.1)

3 (2.8)

 

6 (4.3)

9 (6.5)

T stage

 Tis-T2

68 (19.1)

29 (17.6)

39 (20.4)

0.386

9 (16.4)

78 (25.9)

0.844

43 (15.6)

24 (14.1)

19 (17.9)

0.588

19 (13.8)

24 (17.4)

0.044

 T3

242 (68.0)

118 (71.5)

124 (64.9)

 

39 (70.9)

203 (67.4)

 

32 (19.6)

32 (18.8)

22 (20.8)

 

20 (14.5)

34 (24.6)

 T4

46 (12.9)

18 (10.9)

28 (14.7)

 

7 (12.7)

39 (13.0)

 

179 (64.8)

114 (67.1)

65 (61.3)

 

99 (71.7)

80 (58.0)

N stage

 N0

194 (54.5)

83 (50.3)

111 (58.1)

0.185

23 (41.8)

171 (56.8)

0.101

120 (43.5)

70 (41.2)

50 (47.2)

0.432

57 (41.3)

63 (45.7)

0.767

 N1

98 (27.5)

53 (32.1)

45 (23.6)

 

18 (32.7)

80 (26.6)

 

83 (30.1)

49 (28.8)

33 (31.1)

 

43 (31.2)

40 (29.0)

 N2

64 (18.0)

29 (17.6)

35 (18.3)

 

14 (25.5)

50 (16.6)

 

73 (26.4)

50 (29.4)

23 (21.7)

 

38 (27.5)

35 (25.4)

M stage

 M0

245 (68.8)

109 (66.1)

136 (71.2)

0.107

34 (61.8)

211 (70.1)

0.284

234(84.8)

137 (80.6)

97 (91.5)

0.01

108(78.3)

126 (91.3)

0.003

 M1

48 (13.5)

29 (17.6)

19 (9.9)

 

11 (20.0)

37 (12.3)

 

42(15.2)

33 (19.4)

9 (8.5)

 

30(21.7)

12 (8.7)

 Mx

63 (17.7)

27 (16.4)

36 (18.8)

 

10 (18.2)

53 (17.6)

       

Pathological grading

 Well/moderate

NA

204(73.9)

67 (73.6)

137 (74.1)

0.498

102(73.9)

102 (73.9)

1.000

 Poor/anaplastic

56(20.3)

18 (19.8)

38 (20.5)

 

28(20.3)

28 (20.3)

 Unknown

16(5.8)

6 (6.6)

10 (5.4)

 

8(5.8)

8 (5.8)

Venous invasion

 Negative

235 (66.0)

105 (63.6)

130 (68.1)

0.557

28 (50.9)

207 (68.8)

0.026

184(66.7)

107 (62.9)

77 (72.6)

0.104

85(61.6)

99 (71.7)

0.193

 Positive

70 (19.7)

33 (20.0)

37 (19.4)

 

14 (25.5)

56 (18.6)

 

88(31.9)

59 (34.7)

29 (27.4)

 

51(37.0)

37 (26.8)

 Unknown

51 (14.3)

27 (16.4)

24 (12.6)

 

13 (23.6)

38 (12.6)

 

4(1.4)

4 (2.4)

0 (0.0)

 

2(1.4)

2 (1.4)

Nervous invasion

 Negative

NA

231 (83.7)

75 (82.4)

156 (84.3)

0.181

118 (85.5)

231 (83.7)

0.337

 Positive

45 (16.3)

16 (17.6)

29 (15.7)

 

20 (14.5)

45 (16.3)

TILs extent

 Low

47 (13.2)

33 (20.0)

14 (7.3)

0.002

16 (29.1)

31 (10.3)

<0.001

129 (46.7)

85 (50.0)

44 (41.5)

0.169

59 (42.8)

70 (50.7)

0.184

 High

93 (26.1)

42 (25.5)

51 (26.3)

 

17 (30.9)

76 (25.2)

 

147 (53.3)

85 (50.0)

62 (58.5)

 

79 (57.2)

68 (49.3)

 Unknown

216 (60.7)

90 (54.5)

126 (66.0)

 

22 (40.0)

194 (64.5)

       

No. of LNs dissected

  < 12

80 (22.5)

42 (25.5)

38 (19.9)

0.219

14 (25.5)

56 (18.6)

0.658

39 (14.1)

24 (14.1)

15 (14.2)

0.994

16 (11.6)

23 (16.7)

0.226

  ≥ 12

247 (69.4)

107(64.8)

140 (73.3)

 

38 (69.1)

209 (69.4)

 

237 (85.9)

146 (85.9)

91 (85.8)

 

122 (88.4)

115 (83.3)

 Unknown

29 (8.1)

16 (9.7)

13 (6.8)

 

3 (5.5)

26 (8.6)

       

MS status/MMR status

 MSS/MMR-proficient

243 (68.3)

123 (74.5)

120 (62.8)

0.018

39 (70.9)

204 (67.8)

0.646

176 (63.8)

102 (60.0)

74 (69.8)

0.099

93 (67.4)

83 (60.1)

0.21

 MSI/MMR-deficient

113 (31.7)

42 (25.5)

71 (37.2)

 

16 (29.1)

97 (32.2)

 

100 (36.2)

68 (40.0)

32 (30.2)

 

45 (32.6)

55 (39.9)

CEA (μl/ml)

  ≤ 5

144 (40.4)

59 (35.8)

85 (44.5)

0.151

13 (23.6)

131 (43.5)

0.007

170 (61.6)

106 (62.4)

64 (60.4)

0.532

80 (58.0)

90 (65.2)

0.382

  > 5

85 (23.9)

39 (23.6)

46 (24.1)

 

13 (23.6)

72 (23.9)

 

95 (34.4)

59 (34.7)

36 (34.0)

 

51 (37.0)

44 (31.9)

 Unknown

127 (35.7)

67 (40.6)

60 (31.4)

 

29 (52.7)

98 (32.6)

 

11 (4.0)

5 (2.9)

6 (5.7)

 

7 (5.1)

4 (2.9)

Adjuvant chemotherapy

 Yes

NA

189 (68.5)

58 (63.7)

131 (70.8)

0.082

89 (64.5)

100 (72.5)

0.05

 No

49 (17.8)

15 (16.5)

34 (18.4)

 

23 (16.7)

26 (18.8)

 Unknown

38 (13.7)

18 (19.8)

20 (10.8)

 

26 (18.8)

12 (8.7)

  1. aItalic entries indicate statistical significance